These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 1297600)

  • 1. Stabilization of severe proliferative diabetic retinopathy by long-term treatment with SMS 201-995.
    Mallet B; Vialettes B; Haroche S; Escoffier P; Gastaut P; Taubert JP; Vague P
    Diabete Metab; 1992; 18(6):438-44. PubMed ID: 1297600
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Growth hormone suppression and nonproliferative diabetic retinopathy: a preliminary feasibility study.
    Shumak SL; Grossman LD; Chew E; Kozousek V; George SR; Singer W; Harris AG; Zinman B
    Clin Invest Med; 1990 Oct; 13(5):287-92. PubMed ID: 2276223
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Metabolic effects of long-acting somatostatin analogue (sandostatin) in type I diabetic patients on conventional therapy.
    Osei K; O'Dorisio TM; Malarkey WB; Craig EL; Cataland S
    Diabetes; 1989 Jun; 38(6):704-9. PubMed ID: 2656340
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Octreotide reduces vitreous hemorrhage and loss of visual acuity risk in patients with high-risk proliferative diabetic retinopathy.
    Boehm BO; Lang GK; Jehle PM; Feldman B; Lang GE
    Horm Metab Res; 2001 May; 33(5):300-6. PubMed ID: 11440277
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of the somatostatin analogue octreotide on growth hormone secretion in insulin-dependent diabetics without residual insulin secretion.
    Wurzburger MI; Prelevic GM; Sonksen PH; Balint-Peric LA
    Horm Metab Res; 1992 Jul; 24(7):329-32. PubMed ID: 1516889
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of one year continuous subcutaneous infusion of a somatostatin analogue, octreotide, on early retinopathy, metabolic control and thyroid function in Type I (insulin-dependent) diabetes mellitus.
    Kirkegaard C; Nørgaard K; Snorgaard O; Bek T; Larsen M; Lund-Andersen H
    Acta Endocrinol (Copenh); 1990 Jun; 122(6):766-72. PubMed ID: 2197845
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Therapy of diabetic retinopathy with somatostatin analogues].
    Lang GE
    Ophthalmologe; 2004 Mar; 101(3):290-3. PubMed ID: 15007609
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Progression of diabetic retinopathy during improved metabolic control may be treated with reduced insulin dosage and/or somatostatin analogue administration -- a case report.
    Chantelau E; Frystyk J
    Growth Horm IGF Res; 2005 Apr; 15(2):130-5. PubMed ID: 15809016
    [TBL] [Abstract][Full Text] [Related]  

  • 9. What may be gained from standard photocoagulation during early worsening of diabetic retinopathy? An observational study in type-1 diabetic patients after tightening of glycaemic control.
    Chantelau E
    Diabetes Metab; 2001 Jun; 27(3):366-71. PubMed ID: 11431602
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The efficacy of octreotide in the therapy of severe nonproliferative and early proliferative diabetic retinopathy: a randomized controlled study.
    Grant MB; Mames RN; Fitzgerald C; Hazariwala KM; Cooper-DeHoff R; Caballero S; Estes KS
    Diabetes Care; 2000 Apr; 23(4):504-9. PubMed ID: 10857943
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Continuous subcutaneous octreotide infusion markedly suppresses IGF-I levels whilst only partially suppressing GH secretion in diabetics with retinopathy.
    Hyer SL; Sharp PS; Brooks RA; Burrin JM; Kohner EM
    Acta Endocrinol (Copenh); 1989 Feb; 120(2):187-94. PubMed ID: 2916380
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association Between Vessel Density and Visual Acuity in Patients With Diabetic Retinopathy and Poorly Controlled Type 1 Diabetes.
    Dupas B; Minvielle W; Bonnin S; Couturier A; Erginay A; Massin P; Gaudric A; Tadayoni R
    JAMA Ophthalmol; 2018 Jul; 136(7):721-728. PubMed ID: 29800967
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of the effectiveness of 2-hourly versus 8-hourly subcutaneous injections of a somatostatin analog (SMS 201-995) in the treatment of acromegaly.
    Wang C; Lam KS; Arceo E; Chan FL
    J Clin Endocrinol Metab; 1989 Sep; 69(3):670-7. PubMed ID: 2668325
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Elevated long-term glycated haemoglobin precedes proliferative retinopathy and nephropathy in type 1 (insulin-dependent) diabetic patients.
    Kullberg CE; Arnqvist HJ
    Diabetologia; 1993 Oct; 36(10):961-5. PubMed ID: 8243877
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Panretinal Photocoagulation Versus Ranibizumab for Proliferative Diabetic Retinopathy: Factors Associated with Vision and Edema Outcomes.
    Bressler SB; Beaulieu WT; Glassman AR; Gross JG; Melia M; Chen E; Pavlica MR; Jampol LM;
    Ophthalmology; 2018 Nov; 125(11):1776-1783. PubMed ID: 29980333
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Spontaneous resolution of macular edema after panretinal photocoagulation in florid proliferative diabetic retinopathy.
    Gaucher D; Fortunato P; LeCleire-Collet A; Bourcier T; Speeg-Schatz C; Tadayoni R; Massin P
    Retina; 2009 Oct; 29(9):1282-8. PubMed ID: 19629019
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Progression of diabetic retinopathy and changes in serum insulin-like growth factor I (IGF I) during continuous subcutaneous insulin infusion (CSII).
    Hyer SL; Sharp PS; Sleightholm M; Burrin JM; Kohner EM
    Horm Metab Res; 1989 Jan; 21(1):18-22. PubMed ID: 2925151
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Somatostatin analogue SMS 201-995 in type I diabetes mellitus. Initial experience after repeated administration.
    Plewe G; Nölken G; Krause U; del Pozo E; Beyer J
    Scand J Gastroenterol Suppl; 1986; 119():166-9. PubMed ID: 2876502
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sequence effect in the treatment of proliferative diabetic retinopathy with intravitreal ranibizumab and panretinal photocoagulation.
    Cao G; Xu X; Wang C; Zhang S
    Eur J Ophthalmol; 2020 Jan; 30(1):34-39. PubMed ID: 30539668
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Growth hormone levels in the basal state and after thyrotropin-releasing hormone stimulation in young type 1 (insulin-dependent) diabetic patients with severe retinopathy.
    Agardh CD; Agardh E; Eckert B; Sjöberg U
    Diabetes Res; 1992 Feb; 19(2):81-5. PubMed ID: 1286543
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.